Skip to main content

Drug Discovery Mitochondrial Toxicology

De-Risk Your Drug Discovery Pipeline | Assessing mitochondrial toxicities and liabilities
Don't let mitochondrial‐toxic compounds slip through

Identifying compounds that induce toxicities is an important part of lead‐optimization during drug discovery. However, most commonly used end‐point assays lack the sensitivity to capture many compounds with mitochondrial toxicity, leading to late‐stage failures.

Agilent cell analysis solutions provide real‐time, direct measurements of mitochondrial metabolism with the highest specificity and sensitivity. With these solutions, you can be confident the data you're collecting provides an accurate picture of mitochondrial toxicity risk enabling you to make informed decisions on your drug development pipeline.

No matter your workflow, we have the solution
  • Screening Screening
  • Investigative Investigative
  • Predictive Predictive
  • Mechanistic Mechanistic

Often the initial step in mitochondrial toxicology studies is to screen your compound library to identify any compounds with potential mitochondrial toxicity. With the Agilent MitoXpress Xtra oxygen consumption assay, you can screen your library using a direct measure of mitochondrial metabolism in a high‐throughput 384‐well format. See how

Investigative toxicology studies seek to analyze the level and type of mitochondrial toxicity caused by your compounds to understand their potency and assess preclinical risk. Combine the Agilent Seahorse XFe96 Analyzer with the MitoXpress Xtra oxygen consumption assay for maximum sensitivity and specificity in these studies. See how

In predictive toxicology, both the short and long‐term effects of your compounds and their metabolites on mitochondrial function are analyzed to predict the risk of in vivo mitochondrial toxicity. Combine the Agilent XFe96 Analyzer with 3D human liver microtissues for these studies and investigate the effects of long‐term drug exposure with high sensitivity. See how

In mechanistic toxicology, the impact of your compounds on mitochondrial function is analyzed to better understand the link between observed toxicity and mechanism of action. You can identify which metabolic pathways your compound effects and to what degree using the Agilent Seahorse XFe96 Analyzer with the Mito Stress Test and Real‐Time ATP rate assay. See how

Mitochondrial liability assessment in practice

Learn how Genentech is advancing mitochondrial liability assessment in our on‐demand webinar Challenges in Assessing Mitochondrial Toxicities and Liabilities in Drug Discovery.

Agilent metabolic measurement solutions

Enhance your drug discovery workflow with live cell, real‐time metabolic analysis solutions from Agilent. Learn more about our solutions.

Label‐free assay platform for making metabolic measurements in almost any cell type

The Seahorse XFe96 Analyzer and accompanying assays provide drug discovery scientists with well‐established tools for determining metabolic phenotype, detecting glycolytic and mitochondrial inhibitors, and investigating mitochondrial toxicants. Learn more

Flexible microplate reagents for real‐time fluorescence plate reader‐based assays

Easy‐to‐use kits and reagents for measuring real‐time energy flux and mitochondrial function. Convenient for higher throughput assays as they are performed on TRF‐enabled plate readers with 96 and 384 well formats. Learn more

Streamlined sample preparation workflow to deliver actionable results from your live‐cell analysis

The Bravo automated liquid handling platform coupled with Bravo Seahorse Assay Workbench software streamlines your Seahorse XFe96 assay preparation. Generate the results you need while saving labor in the lab, increasing walk‐away time, and achieving consistent data quality. Learn more

For Research Use Only. Not for use in diagnostic procedures.